Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tirumotecan”

84 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 84 results

Early research (Phase 1)Not Yet RecruitingNCT07702305
What this trial is testing

Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer

Who this might be right for
EGFR-TKI-resistant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
Henan Cancer Hospital 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT06483334
What this trial is testing

Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Who this might be right for
Metastatic Urothelial CarcinomaLocally Advanced Urothelial Carcinoma
Merck Sharp & Dohme LLC 38
Testing effectiveness (Phase 2)Looking for participantsNCT07179783
What this trial is testing

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Who this might be right for
Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic Castration-ResistantProstate Adenocarcinoma With Neuroendocrine Differentiation
Tianjin Medical University Second Hospital 28
Large-scale testing (Phase 3)Looking for participantsNCT07318558
What this trial is testing

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Who this might be right for
Ovarian NeoplasmsOvarian Cancer
Merck Sharp & Dohme LLC 900
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07109284
What this trial is testing

SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer

Who this might be right for
ER+HER2- Breast Cancer
West China Hospital 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07738757
What this trial is testing

SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies

Who this might be right for
Recurrent or Metastatic MSI-H/dMMR Gynecological Malignancies
Peking Union Medical College Hospital 80
Large-scale testing (Phase 3)Looking for participantsNCT06824467
What this trial is testing

Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Merck Sharp & Dohme LLC 770
Testing effectiveness (Phase 2)Looking for participantsNCT06637423
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Who this might be right for
Non-Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC 32
Not applicableLooking for participantsNCT07068542
What this trial is testing

Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer

Who this might be right for
Advanced Thyroid CarcinomaRadioiodine-refractory Differentiated Thyroid CancerPoorly Differentiated Thyroid Carcinoma
Zhejiang Provincial People's Hospital 94
Testing effectiveness (Phase 2)Active Not RecruitingNCT07703228
What this trial is testing

Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Stage IIIB~IVSecond-line Therapy+1 more
Nanfang Hospital, Southern Medical University 38
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07561463
What this trial is testing

Sacituzumab Tirumotecan for Pancreatic Cancer

Who this might be right for
Pancreatic Ductal Adenocarcinoma (PDAC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06706219
What this trial is testing

Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC

Who this might be right for
Non Small Cell Lung Cancer (Stage III)
Hunan Province Tumor Hospital 50
Large-scale testing (Phase 3)Looking for participantsNCT07419295
What this trial is testing

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Who this might be right for
Bladder Cancer
Merck Sharp & Dohme LLC 590
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07662863
What this trial is testing

Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)

Who this might be right for
Bladder CancerMetastatic Urothelial CarcinomaUrothelial Carcinoma+1 more
Fudan University 75
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07153965
What this trial is testing

Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer (TNBC)PD-L1 Positive
Tianjin Medical University Cancer Institute and Hospital 47
Large-scale testing (Phase 3)Active Not RecruitingNCT06074588
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 556
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07108816
What this trial is testing

A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Resectable Stage II-IIIB NSCLC
Henan Cancer Hospital 52
Large-scale testing (Phase 3)Active Not RecruitingNCT06356311
What this trial is testing

Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Who this might be right for
Gastroesophageal Cancer
Merck Sharp & Dohme LLC 450
Testing effectiveness (Phase 2)Looking for participantsNCT07718854
What this trial is testing

Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer

Who this might be right for
Ovarian Clear Cell CarcinomaMetastatic Ovarian CancerRecurrent Ovarian Clear Cell Adenocarcinoma
Tufts Medical Center 50
Large-scale testing (Phase 3)Active Not RecruitingNCT06459180
What this trial is testing

Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Who this might be right for
Cervical Cancer
Merck Sharp & Dohme LLC 686
Next Page